Koesten, Hirschmann & Crabtree, Inc. Pharma Cyte Biotech, Inc. Transaction History
Koesten, Hirschmann & Crabtree, Inc.
- $192 Million
- Q2 2025
A detailed history of Koesten, Hirschmann & Crabtree, Inc. transactions in Pharma Cyte Biotech, Inc. stock. As of the latest transaction made, Koesten, Hirschmann & Crabtree, Inc. holds 1 shares of PMCB stock, worth $1. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1Holding current value
$1% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding PMCB
# of Institutions
29Shares Held
682KCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA194KShares$200,2800.0% of portfolio
-
Geode Capital Management, LLC Boston, MA127KShares$130,4010.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$94,8497.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$85,2080.09% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.8KShares$51,2940.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $21.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...